Effectiveness of omalizumab in a patient with severe asthma and atopic dermatitis
The anti-IgE antibody omalizumab is currently indicated in severe asthma not controlled by standard drug therapy. Recently, new indications for omalizumab were suggested, which include atopic dermatitis (AD), a skin disorder characterized by elevated levels of IgE. We report the case of a 39-year ol...
Main Authors: | C. Incorvaia, C. Pravettoni, M. Mauro, M.-R. Yacoub, F. Tarantini, G.G. Riario-Sforza |
---|---|
Format: | Article |
Language: | English |
Published: |
PAGEPress Publications
2016-01-01
|
Series: | Monaldi Archives for Chest Disease |
Subjects: | |
Online Access: | https://www.monaldi-archives.org/index.php/macd/article/view/401 |
Similar Items
-
Improvement of quality of life in patients with concomitant allergic asthma and atopic dermatitis: one year follow-up of omalizumab therapy
by: Velling P, et al.
Published: (2011-09-01) -
Rapid clinical improvement of atopic dermatitis in an Omalizumab treated patient
by: Susanna Bormioli, et al.
Published: (2019-03-01) -
A review of omalizumab for the management of severe asthma
by: Lin CH, et al.
Published: (2016-07-01) -
The pharmacological mechanisms of omalizumab in patients with very high IgE levels—Clues from studies on atopic dermatitis
by: Tse Wen Chang, et al.
Published: (2012-12-01) -
Omalizumab Treatment for Severe Atopic Asthma in a Real World Montréal Cohort
by: David Haile-Meskale, et al.
Published: (2020-07-01)